GlassScriptPhysician profile
Sara Adams
NPI 1043397391
$2,323.65
in general payments reported to CMS, 2019-2025
27 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $504 · 2021: $140 · 2022: $330 · 2023: $277 · 2024: $148 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $883.45 | 2019-2025 | |
| Pfizer INC. | $230.15 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $167.09 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $162.28 | 2019-2021 | |
| Celgene Corporation | $137.28 | 2022-2025 | Reblozyl, Pomalyst |
| Gilead Sciences, INC. | $122.48 | 2022-2025 | Trodelvy |
| Genentech USA, INC. | $114.05 | 2019-2022 | |
| Amgen INC. | $74.55 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Janssen Biotech, INC. | $52.51 | 2020-2022 | |
| Glaxosmithkline, LLC. | $42.05 | 2025 | Ojjaara |
| Astellas Pharma US INC | $41.88 | 2021 | |
| Eisai INC. | $41.74 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $30.40 | 2020-2023 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.43 | 2025 | |
| Daiichi Sankyo INC. | $21.72 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.31 | 2019 | |
| Jazz Pharmaceuticals INC. | $18.97 | 2020 | |
| Genzyme Corporation | $18.62 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $16.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.35 | 2023 | Enhertu |
| Myovant Sciences INC. | $16.22 | 2022 | |
| Mirati Therapeutics, INC. | $14.44 | 2023 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $14.22 | 2020 | |
| Morphosys, US INC. | $13.85 | 2023 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $12.02 | 2020 | |
| Verastem, INC. | $11.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.